Beryl Drugs logo

Beryl Drugs

BERYLDRUGSLTD NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹11.20 Cr
Volatility
Moderate
P/E Ratio
19.6
EBITDA
₹1.94 Cr
Return on Equity
6.09%
Debt to Equity
0.25
Book Value
₹19.44
EPS
₹1.2
52W High
₹27.6
52W Low
₹15.92

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

3
  • Company has reduced debt.
  • Debtor days have improved from 79.1 to 39.5 days.
  • Company's working capital requirements have reduced from 55.1 days to 39.3 days

Weaknesses

4
  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of 6.60% over past five years.
  • Promoter holding is low: 27.8%
  • Company has a low return on equity of 6.42% over last 3 years.

Growth Rate

Revenue Growth
-16.73% lower than 3Y
Net Income Growth
-20% lower than 3Y
Cash Flow Change
222% higher than 3Y
ROE
-29.27% lower than 3Y
ROCE
-4.7% lower than 3Y
EBITDA Margin (Avg.)
-11.96% lower than 3Y

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
8.18
8.09
7.66
3.21
6.29
5.64
5.4
5.22
4.83
5.16
3.85
5.47
7.57
Expenses
7.05
7.37
6.87
3.19
5.3
5.08
4.81
4.72
4.28
4.43
4.05
4.13
6.92
Operating Profit
1.13
0.72
0.79
0.02
0.99
0.56
0.59
0.5
0.55
0.73
-0.2
1.34
0.65
OPM %
13.81%
8.9%
10.31%
0.62%
15.74%
9.93%
10.93%
9.58%
11.39%
14.15%
-5.19%
24.5%
8.59%
Other Income
0
0
0
0
0
0
0
0
0
0
0
0
0
Interest
0.12
0.1
0.11
0.13
0.21
0.12
0.12
0.08
0.1
0.08
0.09
0.07
0.06
Depreciation
0.28
0.29
0.31
0.32
0.28
0.33
0.31
0.32
0.38
0.39
0.32
0.4
0.32
PBT
0.73
0.33
0.37
-0.43
0.5
0.11
0.16
0.1
0.07
0.26
-0.61
0.87
0.27
Tax %
27.4%
18.18%
16.22%
-16.28%
26%
90.91%
62.5%
-50%
71.43%
96.15%
-72.13%
34.48%
18.52%
Net Profit
0.53
0.27
0.31
-0.35
0.37
0.01
0.05
0.15
0.02
0.01
-0.17
0.56
0.22
EPS in Rs
1.05
0.53
0.61
-0.69
0.73
0.02
0.1
0.3
0.04
0.02
-0.34
1.1
0.43
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
13.23
12.99
10.9
15.08
12.81
12.78
14.03
14.48
26.84
26.73
21.15
19.31
22.05
Expenses
12.5
12.49
10.96
14.04
11.78
11.87
12.58
14.04
24.84
24.45
19.91
16.89
19.53
Operating Profit
0.73
0.5
-0.06
1.04
1.03
0.91
1.45
0.44
2
2.28
1.24
2.42
2.52
OPM %
5.52%
3.85%
-0.55%
6.9%
8.04%
7.12%
10.33%
3.04%
7.45%
8.53%
5.86%
12.53%
11.43%
Other Income
0.18
0.37
0.27
0.69
0.24
0.23
0.64
0.16
0.27
0.4
1.41
0
0
Interest
0.26
0.21
0.2
0.13
0.15
0.32
0.47
0.46
0.47
0.47
0.54
0.34
0.3
Depreciation
0.52
0.41
0.38
0.33
0.32
0.66
1.27
1.09
0.81
1.2
1.25
1.49
1.43
PBT
0.13
0.25
-0.37
1.27
0.8
0.16
0.35
-0.95
0.99
1.01
0.86
0.59
0.79
Tax %
38.46%
32%
18.92%
22.05%
26.25%
68.75%
31.43%
-30.53%
22.22%
23.76%
33.72%
27.12%
—
Net Profit
0.08
0.17
-0.45
0.99
0.59
0.05
0.24
-0.66
0.77
0.77
0.58
0.42
0.62
EPS in Rs
0.16
0.34
-0.89
1.95
1.16
0.1
0.47
-1.3
1.52
1.52
1.14
0.83
1.21
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
5.09
5.09
5.09
5.09
5.09
5.09
5.09
5.09
5.09
5.09
5.09
5.09
Reserves
1.4
1.57
0.79
1.57
2.43
2.53
2.84
2.2
2.97
3.83
4.41
4.79
Borrowings
1.72
1.69
1.72
1.48
3.25
5.23
5.12
5.29
4.54
5.09
4.07
2.44
Other Liabilities
2.71
1.8
2.85
2.69
3.8
4.07
5.6
5.25
4.92
3.48
2.39
2.64
Total Liabilities
10.92
10.15
10.45
10.83
14.57
16.92
18.65
17.83
17.52
17.49
15.96
14.96
Fixed Assets
2.43
2.44
2.25
2.22
1.96
8.6
7.52
6.04
6.03
6.17
6.2
7.04
CWIP
0.24
0
0
0.08
6.24
0
0
0
0
0
0
0
Investments
0.68
0.68
0.49
0.22
0.48
0.56
0.12
0.16
0.15
0
0
0
Other Assets
7.57
7.03
7.71
8.31
5.89
7.76
11.01
11.63
11.34
11.32
9.76
7.92
Total Assets
10.92
10.15
10.45
10.83
14.57
16.92
18.65
17.83
17.52
17.49
15.96
14.96
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0.7
-0.13
0.37
-0.1
3.35
0.18
0.34
-0.29
2.48
0.82
2.64
3.65
Investing
0.02
0.17
0.32
-0.03
-5.01
-1.55
0.26
0.54
-1.3
-1.08
-0.4
-2.16
Financing
-0.09
-0.23
-0.19
-0.36
1.62
1.67
-0.54
-0.43
-1.17
0.1
-1.55
-2.03
Net Cash Flow
0.63
-0.19
0.5
-0.49
-0.04
0.3
0.06
-0.18
0.01
-0.16
0.69
-0.54
Free Cash Flow
0.47
-0.33
0.19
-0.01
-2.87
-1.7
0.1
0.1
1.73
-0.51
1.35
-0.17
CFO/OP
125
6
-833
1
350
36
25
-43
127
45
227
157
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
102
101
102
117
98.02
98.53
118
112
93.83
104
94.23
39.51
Inventory Days
64.34
65.28
151
53.1
39.74
487
1,135
—
246
—
—
117
Days Payable
69.91
34.34
65.24
57.03
93.6
755
1,110
—
758
—
—
53.42
Cash Conversion Cycle
96.5
132
189
113
44.16
-170
143
112
-419
104
94.23
103
Working Capital Days
38.35
58.44
67.31
71.89
-6.55
13.99
38.76
47.14
46.51
57.9
68
39.32
ROCE %
5.2%
5.56%
-2.26%
11.94%
9.94%
4.06%
2.86%
-3.82%
11.6%
11.05%
10.15%
7.18%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Beryl Drugs insights

58 extracted metrics + investor summaries across FY10–FY26.

Log in — free

Shareholding Pattern

Public63.56%Others8.62%Promot.27.82%As ofJun 2026

Documents

Frequently Asked Questions about Beryl Drugs

What does Beryl Drugs Ltd do?
Incorporated in 1993, Beryl Drugs Ltd is in the business of pharmaceuticals manufacturing[1]
Where is Beryl Drugs Ltd (524606) listed?
Beryl Drugs Ltd trades as BERYLDRUGSLTD on the NSE and under code 524606 on the BSE.
Which sector does Beryl Drugs Ltd belong to?
Beryl Drugs Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Beryl Drugs Ltd?
Beryl Drugs Ltd has a market capitalisation of ₹11.2 Cr, which places it in the Small Cap band.
What is the PE ratio of Beryl Drugs Ltd?
Beryl Drugs Ltd trades at a PE ratio of 19.60, on earnings per share of ₹1.2, against a book value of ₹19.44 per share.
What is the 52-week high and low of Beryl Drugs Ltd?
Over the last 52 weeks Beryl Drugs Ltd has traded between ₹15.92 and ₹27.6.
What is the Return on Equity (ROE) of Beryl Drugs Ltd?
Beryl Drugs Ltd reported a return on equity of 6.09%. Its debt-to-equity ratio is 0.25.

Company Information

Incorporated in 1993, Beryl Drugs Ltd is in the business of pharmaceuticals manufacturing[1]

Website beryldrugs.com
Listed 2006-07-25
Face Value ₹ 10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524606.md for Beryl Drugs Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List